RecruitingNot ApplicableNCT06084195
Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging
Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Enrollment
120 participants
Start Date
Dec 19, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The objective of this study is to explore the integration of in vivo and ex vivo of MRI with histology and molecular assessments to advance non-invasive characterization of tumor heterogeneity in high-grade serous ovarian cance
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria5
- Patient aged \>18
- Pathologically proven HGSOC at an advanced stage (FIGO IIIB or IIIC) which can benefit from surgery with or without prior neoadjuvant treatment
- Willingness and ability to comply with planned visits, treatment plan, laboratory tests and other study procedures,
- Patient who has given informed, written and express consent,
- Patient affiliated with a French health insurance scheme.
Exclusion Criteria6
- Early-stage disease (FIGO \<IIIB) or presence of extraperitoneal metastases,
- Patient who will not have surgery
- Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,
- Patient under guardianship, curatorship or safeguarding of justice,
- Pregnant and/or nursing patient,
- Patient with a history of other cancers within 5 years/10 years prior to inclusion
Interventions
BIOLOGICALBlood sample and tissue sample
During the surgery : * Tissus sample : primary tumor and metastasis * blood sample : 3 EDTA tubes * ex vivo MRI data
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06084195
Related Trials
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
NCT0528147131 locations
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT0557936667 locations
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
NCT0500540335 locations
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
NCT055122084 locations
Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer
NCT069768923 locations